Category |
Oncology |
Manuscript Type |
Clinical Trials Study |
Article Title |
Clinical relevance of the use of Dentoxol® for oral mucositis induced by radiotherapy: A phase II clinical trial
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Sebastián Solé, Sergio Becerra, Claudia Carvajal, Piero Bettolli, Hernán Letelier, Alejandro Santini, Lorena Vargas, Alexander Cifuentes, Francisco Larsen, Natalia Jara, Jorge Oyarzún, Eva Bustamente, Benjamín Martínez, David Rosenberg and Tomas Galván |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Sebastián Solé, MD, Assistant Professor, Department of Radiotherapy, Radiomedicine Institute, Américo Vespucio Norte 1314 Vitacura, 8380455, Santiago, Chile. sebasole@gmail.com |
Key Words |
Clinical trial; Dentoxol; Oral mucositis; Prevention; Radiotherapy; Treatment |
Core Tip |
Oral mucositis associated with cancer therapy is a frequent complication. Dentoxol® is a medical solution that has been shown to prevent severe oral mucositis. The clinical significance of Dentoxol® was measured using the results obtained in a randomized controlled clinical trial previously conducted by the same group of researchers. The data obtained show that the clinical impact of Dentoxol® on oral mucositis justifies its incorporation into clinical protocols as a complement to cancer therapy to prevent and/or treat oral mucositis. |
Publish Date |
2022-10-20 06:46 |
Citation |
Solé S, Becerra S, Carvajal C, Bettolli P, Letelier H, Santini A, Vargas L, Cifuentes A, Larsen F, Jara N, Oyarzun J, Bustamante E, Martinez B, Rosenberg D, Galván T. Clinical relevance of the use of Dentoxol® for oral mucositis induced by radiotherapy: A phase II clinical trial.. World J Clin Oncol 2022; 13(10): 813-821 |
URL |
https://www.wjgnet.com/2218-4333/full/v13/i10/813.htm |
DOI |
https://dx.doi.org/10.5306/wjco.v13.i10.813 |